ReviewExperimental and therapeutic medicine2026
Key role of the autonomic nervous system in breast cancer (Review).
Review in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence from tumor neuroscience and clinical observations have implicated the autonomic nervous system (ANS) in breast cancer pathobiology. Sympathetic activation (norepinephrine/β-adrenergic signaling) aligns with pro-angiogenic, pro-invasive programs and distant spread, whereas increased vagal activity is associated with an anti-inflammatory state and restraint of progression. The present review summarizes mechanistic, translational and clinical data supporting a bidirectional regulatory model and evaluates a variety of ANS-targeted strategies, including β-adrenergic modulation, non-invasive vagus nerve stimulation and related neuromodulatory approaches. Whilst biologic plausibility is strong, clinical evidence remains heterogeneous and limited by study design. To the best of our knowledge, no adequately powered randomized trials have demonstrated sufficient survival benefits. The present review outlines principles for standardized autonomic phenotyping (such as heart rate variability), candidate patient selection and trial endpoints to test whether ANS modulation can improve recurrence, metastasis, toxicity and quality-of-life outcomes. Through integrating convergent evidence and articulating testable hypotheses, the present review provides an ANS-informed framework to guide future breast cancer research and care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.